Seres Therapeutics Inc (MCRB):製薬・医療:M&Aディール及び事業提携情報

GlobalDataが発行した調査報告書(DATA904C8300)
◆英語タイトル:Seres Therapeutics Inc (MCRB) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8300
◆発行会社(リサーチ会社):GlobalData
◆発行日:2018年10月
◆ページ数:53
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
Seres Therapeutics Inc (Seres), is a microbiome therapeutics platform company that develops a novel class of biological drugs. The company creates a new class of medicines to treat diseases resulting from functional deficiencies in the microbiome, a condition known as dysbiosis. The company’s lead development candidate, SER-109 is an oral microbiome therapeutic and bacterial spore ecology that is being developed for the prevention of recurrent clostridium difficile infection in adults. Seres’ SER-287 is an oral therapy for the treatment of ulcerative colitis, an inflammatory bowel disease. The company utilizes its microbiome therapeutics platform to identify key alterations in the microbiome that are associated with or lead to specific diseases. Seres is headquartered in Cambridge, Massachusetts, the US.

Seres Therapeutics Inc (MCRB) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Seres Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Seres Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Seres Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Seres Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Seres Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Seres Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
Seres Health Raises USD48 Million in Series C Venture Financing 12
Seres Health Raises USD10 Million in Series B Financing 13
Seres Health Raises US$10.5 Million In Series A Financing Round 15
Partnerships 16
Seres Therapeutics to Enter into Partnership Agreement with MD Anderson and Parker Institute 16
Seres Therapeutics Enters into Agreement with Emulate 17
Seres Therapeutics Enters into Agreement with Massachusetts General Hospital 18
Seres Therapeutics Enters into Research Agreement with Mayo Clinic 19
Seres Therapeutics Enters into Research Agreement with Memorial Sloan Kettering Cancer Center 20
Seres Therapeutics Enters into Agreement with University of Pennsylvania 21
Seres Therapeutics Forms Partnership with Research Institute of St. Joseph’s Hamilton 22
Seres Therapeutics Forms Partnership with Medical University of Graz 23
Seres Health Enters into Research Agreement with Mayo Clinic 24
Licensing Agreements 25
Nestle Health Science Enters into Licensing Agreement with Seres Therapeutics 25
Seres Therapeutics Enters into Licensing Agreement with Mayo Foundation for Medical Education and Research 27
Equity Offering 28
Seres Therapeutics Raises USD153.8 Million in IPO 28
Seres Health Raises USD65 Million in Financing 30
Seres Therapeutics Inc – Key Competitors 31
Seres Therapeutics Inc – Key Employees 32
Seres Therapeutics Inc – Locations And Subsidiaries 33
Head Office 33
Other Locations & Subsidiaries 33
Recent Developments 34
Financial Announcements 34
Aug 02, 2018: Seres Therapeutics reports second quarter financial results and provides operational updates 34
May 09, 2018: Seres Therapeutics Reports First Quarter Financial Results and Provides Operational Updates 36
Mar 08, 2018: Seres Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Updates 38
Nov 08, 2017: Seres Therapeutics Reports Third Quarter 2017 Financial Results 41
Aug 03, 2017: Seres Therapeutics Reports Second Quarter 2017 Financial Results and Provides Update on Operational Progress 43
May 04, 2017: Seres Therapeutics Reports First Quarter 2017 Financial Results and Provides Update on Operational Progress 45
Mar 16, 2017: Seres Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Operational Progress Update 46
Corporate Communications 48
Sep 04, 2018: Seres Therapeutics appoints Meryl Zausner as Board Director 48
Jan 31, 2018: Seres Therapeutics Names Eric D. Shaff to Additional Role of Chief Operating Officer 49
Jul 10, 2017: Seres Therapeutics Strengthens Board of Directors with Appointment of Willard Dere, M.D., Former Amgen Chief Medical Officer 50
Clinical Trials 51
Apr 17, 2018: Seres Therapeutics Presents New Preclinical Data Supporting the Development of Microbiome Therapeutics for Immuno-Oncology at the 2018 American Association for Cancer Research Annual Meeting 51
Nov 07, 2017: Seres Therapeutics Awarded Grant from CARB-X to Support Development of Microbiome Therapeutic Candidate 52
Appendix 53
Methodology 53
About GlobalData 53
Contact Us 53
Disclaimer 53

List of Tables
Seres Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Seres Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Seres Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Seres Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Seres Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Seres Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Seres Health Raises USD48 Million in Series C Venture Financing 12
Seres Health Raises USD10 Million in Series B Financing 13
Seres Health Raises US$10.5 Million In Series A Financing Round 15
Seres Therapeutics to Enter into Partnership Agreement with MD Anderson and Parker Institute 16
Seres Therapeutics Enters into Agreement with Emulate 17
Seres Therapeutics Enters into Agreement with Massachusetts General Hospital 18
Seres Therapeutics Enters into Research Agreement with Mayo Clinic 19
Seres Therapeutics Enters into Research Agreement with Memorial Sloan Kettering Cancer Center 20
Seres Therapeutics Enters into Agreement with University of Pennsylvania 21
Seres Therapeutics Forms Partnership with Research Institute of St. Joseph’s Hamilton 22
Seres Therapeutics Forms Partnership with Medical University of Graz 23
Seres Health Enters into Research Agreement with Mayo Clinic 24
Nestle Health Science Enters into Licensing Agreement with Seres Therapeutics 25
Seres Therapeutics Enters into Licensing Agreement with Mayo Foundation for Medical Education and Research 27
Seres Therapeutics Raises USD153.8 Million in IPO 28
Seres Health Raises USD65 Million in Financing 30
Seres Therapeutics Inc, Key Competitors 31
Seres Therapeutics Inc, Key Employees 32
Seres Therapeutics Inc, Subsidiaries 33

List of Figures
Seres Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Seres Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Seres Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Seres Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Seres Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Seres Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Seres Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Seres Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Seres Therapeutics Inc (MCRB):製薬・医療:M&Aディール及び事業提携情報(Seres Therapeutics Inc (MCRB) - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆